Phase II study of recombinant alpha-interferon and recombinant interleukin-2 metastatic breast cancer.
Ten patients with metastatic breast cancer were treated with a combination of recombinant alpha-interferon and recombinant interleukin-2. The toxicity of treatment was considerable, including one death on therapy. No objective responses were seen.
Walters
R S
RS
Department of Breast and Gynecologic Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030-4009.
Theriault
R L
RL
Holmes
F A
FA
Esparza
L
L
Hortobagyi
G N
GN
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000556:secondary* / Q000628:therapy*; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use
D007370:Interferon Type I; D007376:Interleukin-2; D011994:Recombinant Proteins